Agilent Technologies is engaged in life sciences, diagnostics and applied chemical markets. The company's segments are: Life Sciences and Applied Markets Business, which provides instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products; Diagnostics and Genomics Business, which includes the genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership and biomolecular analysis businesses; and Agilent CrossLab Business, which spans the entire lab with its consumables and services portfolio to improve customer outcomes.

Arcelik is engaged in the commercial and industrial activities in respect of the production, sales and marketing, customer services after sales, exportation and importation of consumer durable goods and consumer electronics. Co. has two segments: white goods reportable segment, which comprises washing machines, dryers, dish washers, refrigerators, ovens, cookers and the services provided for these products; and the consumer goods reportable segment, which comprises televisions primarily with flat screens, computers, cash registers, other electronic devices and the services provided to consumers for these products.

Concert Pharmaceuticals is a clinical stage biopharmaceutical company. The company's pipeline is focused on utilizing its deuterium and proprietary product platform to develop medications designed to enhance patient outcomes in therapeutic areas including autoimmune diseases and central nervous systems disorders. The company's clinical pipeline of product candidates include: CTP-543, which is for the treatment of moderate-to-severe alopecia areata, an autoimmune disease that results in partial or complete loss of hair on the scalp and body; CTP-692, which is for the adjunctive treatment of schizophrenia; and AVP-786, which is for the treatment of agitation associated with Alzheimer's disease.

Cross Country Healthcare provides healthcare staffing, recruiting and workforce solutions. The company's business consists of three business segments: Nurse and Allied Staffing, which provides staffing, recruiting, and workforce solutions including temporary and permanent placement of travel and local branch-based nurse and allied personnel; Physician Staffing, which provides physicians, certified registered nurse anesthetists, nurse practitioners and physician assistants under its Medical Doctor Associates brand; and Other Human Capital Management Services, which is comprised of retained and contingent search services for physicians, healthcare executives, and other healthcare personnel.

Esperion Therapeutics is a pharmaceutical company that develops and commercializes oral, once-daily, non-statin medicines for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). The company's primary products, NEXLETOL? tablet and NEXLIZET? tablets, are oral, once-daily, non-statin LDL-C lowering medicines approved in the U.S. for patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). The U.S. Food and Drug Administration has approved NEXLETOL as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C.

Harte Hanks provides a range of marketing services, in media from direct mail to email. These include: Agency, which provides full-service, customer engagement solutions focusing on direct and digital communications for both consumer and business-to-business markets; digital solutions, which integrates online services within the marketing mix and include: search engine management, display, digital analytics, website development and design, digital strategy, social media, email, e-commerce, and interactive relationship management; mail and product fulfillment solutions where the company provides print on demand, manages product recalls, and distributes literature and other products.

Huron Consulting Group is a consulting firm. The company partners with clients to develop strategies and implement solutions that enable the transformative change its clients need. The company's segments are: Healthcare, which provides care transformation, financial and operational, technology and analytics, and leadership development; Business Advisory, which provides services to large and middle market organizations, not-for-profit organizations, lending institutions, law firms, investment banks and private equity firms; and Education, which provides consulting and technology solutions to higher education institutions and academic medical centers.

Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. The company's marketed product, Ocaliva? (obeticholic acid or OCA), is an farnesoid X receptor agonist approved in the U.S., the European Union and several other jurisdictions for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. In addition to, the company is developing OCA for multiple indications, including nonalcoholic steatohepatitis.

Mersana Therapeutics is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates (ADCs) for cancer patients. The company's primary product candidate, XMT-1536, is an ADC targeting NaPi2b, an antigen broadly expressed in ovarian cancer and non small cell lung cancer. In addition, the company has established research and development partnerships with Merck KGaA and Asana Biosciences for the development and commercialization of additional ADC product candidates against a limited number of targets selected by the company's partners based on its Dolaflexin platform.

Veru is an oncology and urology biopharmaceutical company developing medicines for the management of prostate cancer. The company's prostate cancer pipeline includes: VERU-111, which targets and disrupts alpha and beta tubulin subunits of microtubules in cells to treat metastatic prostate cancer patients whose disease is resistant to both castration and androgen-blocking agents; Zuclomiphene citrate, an oral nonsteroidal estrogen receptor agonist used to treat hot flashes caused by androgen deprivation therapy (ADT) in men with prostate cancer; and VERU-100, a proprietary peptide formulation for ADT with multiple potential for the treatment of prostate cancer.